No Data
No Data
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
MicroPort Scientific Forecasts Decline in Net Loss for H1 on Higher Revenue
MicroPort Scientific (HKG:0853) forecasts a "significant" decline in its net loss for the six months ended June 30 due to a 17% rise in revenue, according to a Monday filing with the Hong Kong Stock
MicroPort CardioFlow Medtech Expects Up to 28% Rise in H1 Revenue
MicroPort CardioFlow Medtech (HKG:2160) forecasts revenue to surge 22% to 28% to between 215 million yuan and 225 million yuan in the first half, according to a Thursday filing with the Hong Kong Stoc
Heart Medical (02160) expected to see a year-on-year increase of about 22% to 28% in mid-term revenue of Hong Kong stock connect.
Jingu Finance News | Heart Medical (02160) announced that it expects its income for the six months ending June 30, 2024 to be between RMB 0.215 billion and RMB 0.225 billion, a growth of about 22% to 28% from the same period last year. The growth in income is mainly attributed to: (i) the continuous progress of the group's transcatheter aortic valve implantation (TAVI) products in China, which drives the growth of TAVI product implants and accessory product usage, thereby increasing revenue. During the reporting period, the group's TAVI products were newly introduced to more than 50 hospitals in China, for a total of more than 600 hospitals; (ii) the affiliated pub
Heart-Link Medical's mid-term revenue is expected to be approximately 0.215 billion to 0.225 billion yuan, a year-on-year growth of about 22% to 28%.
Mindray Medical -B (02160) announced that the group expects revenue for the six months ending June 30, 2024 to be between 0.215 billion yuan and 0.225 billion yuan, an increase of about 22% to 28% compared to the same period last year.
Xintong Medical -B (02160) is expected to have a mid-term revenue of approximately 0.215 billion yuan to 0.225 billion yuan, an increase of approximately 22% to 28% year-on-year.
Heart Access Medical -B(02160) released an announcement that the group expects its revenue to... for the six months ending on June 30, 2024.
No Data